BioSpace News Archive

PTC Therapeutics, Inc. announced the submission of the sepiapterin MAA to the European Medicines Agency.

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved the supplemental new drug application for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.

Bio-Techne Corporation is pleased to announce that Lunaphore, part of Bio-Techne’s Spatial Biology Division, is partnering with Nikon Instruments Inc. to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor.

Canadian-based Noze, a global leader in the breath-based diagnostic space, announced it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation’s total grant funding to Noze to $1.8 million.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM) today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs.

Personalis, Inc. (Nasdaq: PSNL) announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.

Vaxxinity, Inc. announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.